Boston Scientific (NYSE:BSX) Hits New 12-Month High on Analyst Upgrade

Shares of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week high during trading on Tuesday after Oppenheimer upgraded the stock from a market perform rating to an outperform rating. Oppenheimer now has a $125.00 price target on the stock, up from their previous price target of $118.00. Boston Scientific traded as high as $109.42 and last traded at $108.45, with a volume of 282959 shares. The stock had previously closed at $108.14.

Several other equities research analysts also recently commented on the stock. Citigroup reaffirmed a “buy” rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Raymond James Financial lifted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Morgan Stanley increased their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, May 16th. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They issued an “outperform” rating and a $118.00 price target for the company. Finally, Robert W. Baird upped their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $117.79.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock valued at $18,397,457. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $26,000. 1248 Management LLC bought a new position in shares of Boston Scientific in the 1st quarter worth about $26,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Finally, Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $27,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.0%

The firm has a market cap of $160.25 billion, a price-to-earnings ratio of 64.38, a PEG ratio of 2.60 and a beta of 0.65. The firm has a 50 day moving average of $104.85 and a 200 day moving average of $102.22. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.